Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial

Fig. 2

Efficacy of PAAG. a A swimmer plot illustrating PFS for the entire cohort (n = 66), with colours indicating the best overall response (BOR). Partial response (PR), stable disease (SD), and progressive disease (PD) are shown in green, blue, and red bars, respectively. The length of the bars represents the duration from enrolment to PD. Death and progression events are represented by circles and triangles, respectively. b Waterfall plot of the best percent change in target lesion diameter from baseline, coloured according to BOR (n = 66). The pentagram represents that the patient showed a decrease in the diameter of the target lesion, but due to the presence of cancerous ascites, the overall evaluation indicated PD. c Spider plot of the change in target lesion diameter from baseline (n = 66)

Back to article page